Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wattana Karnpaet PCLBKK:NEW 85 EV-to-EBITDA is 8.55 as of Aug. 19, 2026, which is 20% below its 10-year median of 10.72. GuruFocus rates BKK:NEW with a GF Score™ of 85/100 and a GF Value™ of ฿96.58 (Fairly Valued). The stock has 1 warning sign investors should review. Among 512 Healthcare Providers & Services companies, Wattana Karnpaet PCL ranks better than 62.7% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Wattana Karnpaet PCL's enterprise value is ฿859.9 Mil.
Wattana Karnpaet PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ฿100.6 Mil. Therefore, Wattana Karnpaet PCL's EV-to-EBITDA for today is 8.55.
The historical rank and industry rank for Wattana Karnpaet PCL's EV-to-EBITDA or its related term are showing as below:
BKK:NEW'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 3.57 Med: 10.72 Max: 23.71
Current: 8.55
During the past 13 years, the highest EV-to-EBITDA of Wattana Karnpaet PCL was 23.71. The lowest was 3.57. And the median was 10.72.
BKK:NEW's EV-to-EBITDA is ranked better than 62.7% of 512
companies
in the Healthcare Providers & Services industry
Industry Median: 10.72
vs BKK:NEW: 8.55
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Wattana Karnpaet PCL's PE Ratio (TTM) for today is calculated as:
Wattana Karnpaet PCL's share price for today is ฿95.00.
Wattana Karnpaet PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿4.070.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Wattana Karnpaet PCL's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Wattana Karnpaet PCL's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wattana Karnpaet PCL EV-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Wattana Karnpaet PCL's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Wattana Karnpaet PCL's EV-to-EBITDA falls into.
Wattana Karnpaet PCL's current Enterprise Value is ฿859.9 Mil.
Wattana Karnpaet PCL's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿100.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wattana Karnpaet PCL (BKK:NEW) has a EV-to-EBITDA of 8.55 as of Aug. 19, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Wattana Karnpaet PCL. This is 20% below median its historical median of 10.72. Over the past decade, Wattana Karnpaet PCL's EV-to-EBITDA has ranged from 3.57 to 23.71. According to the industry distribution chart, Wattana Karnpaet PCL ranks #191 out of 512 companies in the Healthcare Providers & Services industry, placing it in the top 37.3%.
Is Wattana Karnpaet PCL's EV-to-EBITDA too high?
Wattana Karnpaet PCL's current EV-to-EBITDA of 8.55 is 20% below median its 10-year median of 10.72. Over the past 10 years, this metric has ranged from a low of 3.57 to a high of 23.71. The Healthcare Providers & Services industry median EV-to-EBITDA is 10.72. Wattana Karnpaet PCL's value of 8.55 is 20.2% below this industry median. Based on the distribution chart, Wattana Karnpaet PCL ranks #191 out of 512 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Wattana Karnpaet PCL has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wattana Karnpaet PCL's EV-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Wattana Karnpaet PCL ranks #191 out of 512 companies for EV-to-EBITDA. This puts Wattana Karnpaet PCL in the upper half of its industry. The industry median EV-to-EBITDA is 10.72. Wattana Karnpaet PCL's value of 8.55 is 20.2% below this benchmark. Historically, Wattana Karnpaet PCL's own EV-to-EBITDA has ranged from 3.57 to 23.71 over the past decade. While the company's 10-year median is 10.72 vs. the industry median of 10.72, Wattana Karnpaet PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Healthcare Providers & Services company?
The median EV-to-EBITDA among Healthcare Providers & Services companies is 10.72, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wattana Karnpaet PCL's current EV-to-EBITDA of 8.55 is 20.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Wattana Karnpaet PCL. For the Healthcare Providers & Services industry, the median EV-to-EBITDA is 10.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wattana Karnpaet PCL's current EV-to-EBITDA is 8.55, which is 20% below median its own 10-year median of 10.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wattana Karnpaet PCL stock overvalued right now?
Based on GuruFocus' analysis, Wattana Karnpaet PCL (BKK:NEW) is currently considered Fairly Valued. The stock's GF Value™ is ฿96.58, compared to a current price of ฿95.00 — trading 1.6% below its estimated fair value. The current EV-to-EBITDA is 8.55, which is 20% below median its 10-year median of 10.72 and 20.2% below the Healthcare Providers & Services industry median of 10.72. Wattana Karnpaet PCL's overall GF Score™ is 85/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Wattana Karnpaet PCL (BKK:NEW), the current EV-to-EBITDA is 8.55 as of Aug. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wattana Karnpaet PCL (BKK:NEW) Overvalued in 2026?
Based on GuruFocus' analysis, Wattana Karnpaet PCL stock appears to be undervalued.
The current stock price of ฿95.00 is trading 1.6% below its estimated GF Value™ of ฿96.58.
GuruFocus considers Wattana Karnpaet PCL to be Fairly Valued.
Key valuation signals for BKK:NEW:
EV-to-EBITDA: 8.55 (20% below median its 10-year median of 10.72)
GF Value™: ฿96.58 vs. price of ฿95.00 (1.6% below fair value)
Industry Position: 20.2% below the Healthcare Providers & Services median (#191 of 512)
No single metric tells the full story. See the BKK:NEW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wattana Karnpaet PCL is engaged in the operation of a hospital under the name North Eastern Wattana Hospital. It has a single segment of operation, namely the hospital and medical trading business. The company earns revenue from hospital, revenue from sales of medicines, and revenue from hospital rooms, which are derived from the provision of services to various types and a large number of customers. Geographically, the company's operations are carried out in Thailand.
85GF Score
Get the complete analysis for BKK:NEW
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:NEW has been successfully added to your 
